CLOs on the Move


 
Learn how to manage stress, reach personal goals, lift your mood and improve your outlook on life. Our personalized program can help you regain emotional health and well-being through private, one-on- one sessions with professional therapists and coaches via phone or video chat. Learn techniques for managing stress and setting personal goals, and improve your mood and outlook on life.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.ableto.com
  • 320 W. 37th Street 7th floor
    New York, NY USA 10018
  • Phone: 866.287.1802

Executives

Name Title Contact Details

Similar Companies

Saint Charles Health System

Saint Charles Health System, Inc., headquartered in Bend, Ore., owns and operates St. Charles Bend, Madras, Redmond and Prineville. It also owns family care clinics in Bend, Prineville, Redmond and Sisters. St. Charles is a private, not-for-profit Oregon corporation and is the largest employer in Central Oregon with more than 3,800 caregivers. In addition, there are more than 350 active medical staff members and nearly 200 visiting medical staff members who partner with the health system to provide a wide range of care and service to our communities.

Saint Francis Health Services

Saint Francis Health Services is a Morris, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Creative Community Living

Creative Community Living is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Winfield, KS. To find more information about Creative Community Living, please visit www.cclccl.org

Craig Medical Distribution

Craig Medical Distribution is a Vista, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.